Trial Profile
PrasugrEl moNotherapy after DrUg eLUting stent deployMent as a Management Of patients who are uNsuitable for lOng-term dual antiplatelet therapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Jun 2022
Price :
$35
*
At a glance
- Drugs Prasugrel (Primary)
- Indications Cardiovascular disorders; Haemorrhage
- Focus Adverse reactions
- Acronyms PENDULUM; PENDULUM mono
- 17 May 2022 Results of 24 month analysis from pendulum mono study published in the Circulation Journal
- 11 Feb 2021 Results comparing outcomes of prasugrel single antiplatelet therapy (SAPT) vs. dual antiplatelet therapy (DAPT) in Japanese percutaneous coronary intervention (PCI) patients with high bleeding risk from two studies (PENDULUM Mono & PENDULUM Registry), published in the Circulation Journal.
- 12 Jan 2021 Status changed from active, no longer recruiting to completed.